

Annex B: COVAX Reporting Framework

Section A: Update on Gavi's COVAX Facility and COVAX AMC Monitoring, Evaluation and Learning (MEL) strategy

The Gavi Secretariat presented its proposed MEL approach to the Gavi Board in December 2020. Since then, we have further refined this approach and begun implementing key aspects of the strategy. The approach is intended to be holistic in nature, spanning from inputs through to impact across the COVAX Facility and COVAX AMC, and complementary to work being led by other COVAX partners and the wider global health community. It is intended to support both accountability and learning perspectives and will need to evolve and adapt over time to reflect the changing nature and needs of COVAX. It has close linkages to the Secretariat's and broader COVAX Risk Management and Assurance work.

The table below provides some of the key highlights and updates on progress against the core elements of Gavi's COVAX Facility and COVAX AMC MEL Strategy since the December 2020 Gavi Board.

MEL strategy component	Key activity	Highlights / update (May 2021)
<i>Cross-cutting</i>	COVAX Theory of Change	<p>Core COVAX Theory of Change shared with December 2020 Gavi Board</p> <p>Updated COVAX Theory of Change (integrating 2022 strategy) under development, incorporating feedback from core partners</p>
<i>Monitoring</i>	COVAX Reporting Framework	<p>Draft COVAX Reporting Framework shared with December 2020 Gavi Board (indicators only)</p> <p>COVAX Reporting Framework (indicators and targets) shared with May 2021 PPC</p> <p>COVAX Reporting Framework (indicators, targets and actuals) shared with June 2021 Gavi Board</p>
	Complementary monitoring to COVAX Reporting Framework	COVAX Facility and Gavi Secretariat teams are expanding the set of complementary monitoring metrics being tracked internally (to be used, for example, for programme management, course correction and monitoring the evolution of COVAX)
	Core country monitoring and reporting on COVID-19 / COVAX	WHO-UNICEF Joint Reporting Form COVID-19 module (monthly reporting) launched in March 2021

Evaluation	COVAX Facility and COVAX AMC Evaluation Design, Evaluability and Baseline Study	Request for Proposals launched in April 2021 Finalised evaluation design and evaluability report expected late 2021 Finalised baseline study report expected January 2022
	Multi-Stage Evaluation of COVAX Facility and COVAX AMC	Subject to discussions with Evaluation Advisory Committee and to be informed by Evaluation Design, Evaluability and Baseline Study. Tentative expectation is to have a multi-stage, mixed methods evaluation that spans design and process through results, outcomes and impact. Timeline will be mapped to COVAX Facility and COVAX AMC key milestones and governance cycles (such as the COVAX AMC mid-term review).
Learning	COVAX design, results, impact, challenges, and lessons learned from COVAX for 5.0 & future pandemics	Will be incorporated into the Gavi-commissioned independent multi-stage evaluation of the COVAX Facility and COVAX AMC
	Learning syntheses on a rolling basis (more rapid in nature and to inform course-correction and continuous improvement)	Doing on a rolling prioritization basis. Examples include: <ul style="list-style-type: none"> • Documentation and synthesis of early COVAX decisions, rationale, assumptions and risks • First allocation rounds synthesis • Humanitarian buffer processes and implementation learning • COVID-19 Delivery Support
	COVAX early introductions	Coordinating with partners to align on early introduction learnings. For example, maximising use of established learning networks and contributing to cross-Alliance efforts on real-time monitoring and learning of implementation challenges

Section B: Overview of the COVAX Reporting Framework

The COVAX Reporting Framework contains topline performance metrics spanning from inputs through to impact, mapped to the COVAX Core Theory of Change. As noted above, the Theory of Change is currently being re-reviewed and updated, incorporating feedback from core partners to better capture specific nuances and to more appropriately reflect COVAX Facility and COVAX AMC aspects. The TOC is a tool that will be updated as COVAX evolves.

It is important to note that the Framework aims to strike an appropriate balance between metrics that measure aspects of COVAX that Gavi has accountability for, while retaining a high-level end-to-end perspective of COVAX Facility and COVAX AMC goals and objectives. It incorporates both metrics that measure performance directly attributable to COVAX Facility and COVAX AMC as well as performance metrics where COVAX plays a more contributory role.

While the Gavi Secretariat has taken the lead on developing the COVAX Reporting Framework, a number of consultations with core COVAX partners as well as feedback on key metrics shared by other stakeholders have fed into the current set of metrics and targets.

In terms of other aspects to note while reading the COVAX Reporting Framework:

- **Indicator definitions:** An appendix (Appendix 2) containing COVAX Reporting Framework indicator definition sheets is available on BoardEffect.
- **Targets:** Given the evolving nature of the COVID-19 pandemic and the linked discussions on the future role and goals of COVAX, we have only proposed targets through till end 2021 at this point in time. The COVAX Reporting Framework will be updated in due course to reflect agreed future COVAX vision, goals and targets, and may be improved over time following feedback from the Evaluation Design, Evaluability and Baseline Study, for example. Not all metrics have targets proposed. We used three principles to establish targets: 1) ***Ensure consistency with targets already in public domain / sensitized with key stakeholders;*** 2) ***Targets should exist where appropriate and meaningful;*** and 3) ***Monitoring directionality is sometimes sufficient or most appropriate.***
- **Outcome metrics:** The methodology, including the extent of data triangulation used for calculating both persons vaccinated and coverage for COVID-19 and supported by COVAX, is still being refined. The methodology is being developed with Alliance partners.
- **Impact metrics:** Note that we are still exploring options related to key impact metrics (namely deaths averted and metrics measuring social and economic impact). We intend to consider both metrics and different modelling methods more fully prior to determining final inclusion in the COVAX Reporting Framework. We will provide an update accordingly to the Gavi Board in December 2021.

- **Complementary monitoring beyond the COVAX Reporting Framework:** *As noted above, the Gavi Secretariat and the Office of the COVAX Facility are monitoring a broader set of performance, implementation and learning metrics than those included in the COVAX Reporting Framework to ensure robust programme management and to facilitate course correction over time, as required.* Key examples here include vaccine wastage, diversion and / or misuse of vaccines.
- **First report of actuals:** This paper is the first time we are reporting actuals and data for COVAX Reporting Framework. The data compiled for this first report was collected from 13 May-26 May 2021. This first report does not share data against all levels of disaggregation. We intend to share further analysis and a disaggregated view of persons vaccinated and coverage in particular in subsequent updates. The COVAX Reporting Framework will be updated with actuals on a quarterly basis going forward.

Section C: The COVAX Reporting Framework

Acronyms:

AMC:	COVAX Advance Market Commitment
SFPs:	Self-financing Participants
CP:	Committed Purchase (self-financing participant)
OP:	Optional Purchase (self-financing participant)
HB:	Humanitarian Buffer
NDVP:	National Deployment and Vaccination Plan (for COVID-19)

COVAX Input Metrics (1 of 2)

Rapid development of safe, suitable and efficacious covid-19 vaccines

1.0 Number of eligible COVID-19 vaccine candidates listed by the WHO for emergency use / prequalified with signed COVAX advance purchase agreements (APAs)

5 vaccine candidates against target of 10 candidates by end 2021



- Currently 6 COVID-19 vaccine candidates are listed by WHO for emergency use / prequalification
- COVAX is continuing to engage with most manufacturers with candidates in late-stage development and those with emergency approvals & will continue to expand the portfolio with new candidates in the coming months.
- NB: COVAX has signed APAs with Novavax for the NVX-CoV2373 candidate & SII for the NVX-CoV2373 (“Covovax”) candidate, but WHO EUL expected later in 2021 for these.

Pooled demand and vaccine financing secured

2.0 Number of economies confirmed as COVAX participants

187 total confirmed COVAX participants
88 confirmed AMCs of 92 AMC-eligible



- Burundi, Eritrea and United Republic of Tanzania have yet to join COVAX AMC; Marshall Islands opted out of COVAX AMC (needs sufficiently met through other means)
- There are currently 99 Self-financing participants and 88 confirmed COVAX AMC participants

2.1 Number of approved Humanitarian Buffer requests

N/A

- COVAX aspires to launch Humanitarian Buffer materials and receive applications by end June 2021

COVAX Input Metrics (2 of 2)

COVAX REPORTING FRAMEWORK
Data compiled: 13 – 26 MAY 2021*

Pooled demand and vaccine financing secured (cont.)

3.0 Number of AMC92 economies completing some cost-sharing for doses

N/A – expected later in 2021

- COVAX aspires to mobilise \$1bn through cost-sharing by end 2021
- To date, 53 participants have expressed demand for >500M additional doses to be purchased through cost-sharing
- Legal agreements and financial processes for cost-sharing will be shared in early summer 2021

4.0 Total resources mobilised for the COVID-19 Advance Market Commitment (COVAX AMC) innovative financing mechanism

**\$9.6bn USD raised
against target of \$8.3bn USD
by end 2021**



- Figure reported represents pledges from direct donor contributions. IFFIm, Foundations, Corporations and Organisations as well as the European Commission grant.
- COVAX aspires to mobilise an additional \$1bn through cost-sharing


**Actual for indicator 4.0 incorporates the pledges from the COVAX AMC Summit on June 2nd 2021*

COVAX Process Metrics (1 of 2)

Secure vaccine supply

5.0 Number of doses contracted with signed APAs through COVAX

2.5 billion doses contracted against target of 2 billion doses by end 2021



- 2,500 million doses (1,334 million Committed doses; 1,116 Optional doses)
- These actuals are based on APAs signed for seven candidates: Pfizer/BioNTech: BNT162b2, AstraZeneca/University of Oxford: AZD1222, SII-AstraZeneca: AZD1222 (“Covishield”), Janssen: Ad26.COVS.2.S, Moderna: mRNA-1273, Novavax: NVX-CoV2373 and SII/Novavax: NVX-CoV2373 (“Covovax”)
- These doses are to be delivered through 2021 and 2022.
- Note that Novavax and SII-Novavax have not yet received WHO EUL but are expected to receive this later in 2021.

5.1 Number of doses shared (donated) through COVAX

604,800 doses with further negotiations underway

- These 604,800 doses were shared by France
- Initial shared doses are expected to be small volumes (as pilots), but negotiations have laid the legal and operational groundwork for more efficient and streamlined future dose sharing of expected large volumes
- Five countries made new commitments during the COVAX AMC Summit on June 2nd to donate more than 54 million vaccine doses to lower-income countries, including through COVAX, to bridge short-term supply challenges.

6.0 Weighted average price per dose for COVAX-supported doses

\$3.54 USD per dose on average for COVAX-supported doses

- This value is calculated based on the Pfizer/BioNTech: BNT162b2, AstraZeneca/University of Oxford: AZD1222 and SII-AstraZeneca: AZD1222 (“Covishield”) vaccines
- The estimate is calculated based on doses shipped (rather than doses contracted or allocated) to COVAX AMC and SFP participants

COVAX Process Metrics (2 of 2)

Allocate, perform readiness preparation and deploy COVID-19 vaccines

7.0 Rolling average proportion of COVAX participants receiving equitable allocation

99%
against target of >80%



- This indicator measures how well the algorithm was able to allocate doses according to established equality logic rules for an allocation round.
- The closer the value is to 100%, the more equitable allocation achieved.
- The reported percent represents the proportion of applicable participants within one pallet size of their expected total coverage level.
- The algorithm factors in different pallet sizes across different vaccines.

8.0 Number of COVAX-supported doses delivered to economies/HB recipients with confirmed receipt

71.9 million doses delivered
against target of 2 billion doses
by end 2021



- Progress has been significantly impacted by current supply constraints
- Doses have so far been delivered to 125 COVAX participants
- Of the 604,800 doses shared to date, 105,600 of these doses had been delivered to COVAX participants (20 May 2021)

9.0 Median time from confirmation as COVAX participant to first receipt of COVAX-supported doses

Median of 92 days from confirmation as
COVAX participant to receipt of first
COVAX-supported doses

- There are notable outliers related to receipt of COVAX-supported doses. India was the first COVAX participant to receive doses on the 19th of January. 125 participants received doses between Jan and mid-May 2021.
- The range of days consisted of a minimum of 30 to a maximum of 215 days
- At present, there are 35 active COVAX participants still awaiting receipt of COVAX doses

10.0 COVAX AMC participant readiness for introduction of COVID-19 vaccine: Number of COVAX AMC participants who had their NDVPs assessed as ready by Regional Review Committees

88 COVAX AMC participant
NDVPs reviewed and approved

- 100% of COVAX AMC participant submitted NDVPs were approved and deemed ready by Regional Review Committees
- 19 SFPs have also shared their NDVPs (although not formally reviewed)

10.1 COVAX AMC participant readiness for scale-up of COVID-19 vaccines: Number of occasions where doses are re-allocated due to non-completion of post-allocation checks

6 occasions across
three Allocation Rounds to date

- All 6 reallocation instances took place in Allocation Round 2
- Doses were re-allocated for the following reasons: non-completion of regulatory approval; delays related to indemnification and liability; programmatic readiness such as absorptive capacity or civil unrest.
- Post-allocation changes based on refusals related to product preference, safety concerns or variant concerns are monitored separately

COVAX Output Metrics

COVAX REPORTING FRAMEWORK

Data compiled: 13 – 26 MAY 2021

Vaccine introduction and roll-out

11.0 Percentage of COVAX participants that administer COVAX-supported doses as part of their COVID-19 programme

67% of 187 confirmed COVAX participants against target of 100% by June 2021



85% of 147 COVAX participants* who have ever received an allocation administer COVAX-supported doses as part of their COVID-19 programme



- 125 total confirmed COVAX participants are administering COVAX supported doses as part of their COVID-19 programme:
 - 76 AMCs (including CAR and Madagascar who received doses through redistribution from another participant) and 49 SFPs
 - 36 COVAX participants to date have *launched* their national COVID-19 programmes with COVAX-supported doses
- 125 of 147 participants who have received an allocation are administering COVAX-supported doses as part of their COVID-19 programme (85%).

*This denominator (147) excludes the 27 participants represented by the EC for allocation purposes, as well as 13 participants who have not received an allocation due to opt-outs, voluntary delays or unmet financial commitments.

12.0 Number of COVID-19 Vaccine Delivery Support requests approved

7 Bridge Funding requests approved

- This metric incorporates both exceptional (Bridge) funding support approved by the Gavi Board in December 2020 and COVID19 Delivery and System Strengthening funding (subject to Gavi Board approval in June 2021). It does not include support specific to COVID-19 Technical Assistance nor Cold Chain Equipment.
- 7 bridge funding requests approved (exceptional delivery support), with additional 4 requests under review and 13 requests under preparation by participants as of 25 May 2021

13.0 Total resources (USD\$) disbursed to COVAX AMC participants through COVID-19 Vaccine Delivery support

\$4m USD disbursed to 7 Bridge Funding participants

- \$4m disbursed to 7 approved Bridge Funding participants as of 25 May 2021
- COVID19 Delivery and System Strengthening funding subject to Gavi Board approval in June 2021

NOTE: We may explore the inclusion of a composite metric measuring outputs of COVID-19 Vaccine Delivery Support, but this will be developed post the June 2021 Gavi Board and upon finalisation of COVID-19 Delivery & System Strengthening operationalisation

COVAX Outcome Metrics

Vaccine delivery and target populations vaccinated

NB: These are initial estimates. The methodology for COVAX specific estimates is still under refinement by the Alliance. Highlights from further analysis and disaggregated view of persons vaccinated and coverage will be shared in subsequent updates.

Data used were compiled 13 May 2021.

14.0 Persons vaccinated with COVID-19 vaccines

965 million individuals have received at least a first dose

- **Vaccinated through COVAX and non-COVAX doses**
- AMC: 189 million individuals have received at least a first dose
- SFP: 257 million individuals have received at least a first dose
- 299 million individuals are fully vaccinated

14.1 Persons vaccinated with COVID-19 vaccines supported by COVAX

30 million individuals have received at least a first dose supported by COVAX

- AMC: 21 million individuals have received at least a first dose supported by COVAX
- SFP: 8.8 million individuals have received at least a first dose supported by COVAX
- 10 million individuals are fully vaccinated through COVAX-supported doses

15.0 COVID-19 vaccination coverage

12.4% of the world's population have received at least a first dose

- **Vaccinated through COVAX and non-COVAX doses**
- AMC: 4.8% of population have received at least a first dose
- SFP: 8.0% of population have received at least a first dose
- 3.8% of the world's population are fully vaccinated

15.1 COVID-19 vaccination coverage supported by COVAX

0.42% of the total population of COVAX participants have received at least a first dose supported by COVAX against a target of 20%* by end 2021



- AMC: 0.54% of population have received at least a first dose supported by COVAX
- SFP: 0.27% of population have received at least a first dose supported by COVAX
- 0.14% of the total population of COVAX participants are fully vaccinated through COVAX-supported doses
- * Target is at least 20% or to reach coverage level requested by participants if less than 20%

COVAX Impact Metrics

Reduced morbidity and mortality due COVID19

16.0 Cumulative number of reported COVID-19 cases

**122.6 million COVID-19 cases*
in 187 confirmed COVAX participants**

- SFP: 83.3 million cumulative cases
- AMC: 39.3 million cumulative cases
- Note: cumulative between 13 Dec 2019 and 25 May 2021

17.0 Cumulative number of reported COVID-19 deaths

**2.7 million COVID-19 deaths*
in 187 confirmed COVAX participants**

- SFP: 2.1 million cumulative deaths
- AMC: 582,000 cumulative deaths
- Note: cumulative between 13 Dec 2019 and 25 May 2021

18.0 Number of COVID-19 deaths averted (TBC)

N/A

- NB: This metric and the methodology behind it is still under development.
- An update will be provided to the Gavi Board in December 2021

Reduced social and economic impacts

19.0 Proxy metrics related to social and economic impacts (TBC)

N/A

- NB: This metric and the methodology behind it is still under development.
- An update will be provided to the Gavi Board in December 2021